Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
1
|
| pubmed:dateCreated |
1997-2-11
|
| pubmed:abstractText |
Using a combination of intensive chemotherapy and G-CSF, we conducted a prospective trial designed to improve the complete remission (CR) rate in patients with AML evolving from a primary documented myelodysplastic syndrome (sAML) and therapy-related AML (tAML). Thirty-four patients (median age 61 years) with sAML (25 patients) or tAML (nine patients) entered the study. Induction course consisted of idarubicin (12 mg/m2 of body-surface area per day for 3 days) and intermediate-dose (ID) cytarabine in the 24 younger patients (1 g/m2 of body-surface area as a 2 h infusion every 12 h for 5 days) or standard-dose (SD) cytarabine in the 10 older patients (100 mg/m2 of body-surface area per day as a continuous infusion for 7 days), followed by G-CSF until neutrophil recovery or treatment failure. Nineteen patients (56%, 13/24 in the ID group and 6/10 in the SD group) achieved a CR (14/25 sAML and 5/9 tAML). Early death occurred in four patients, but four additional patients died in CR from treatment-related toxicity (overall toxic death rate 24%). Initial cytogenetics was available in 33 patients. The CR rate was significantly lower in patients with unfavorable cytogenetics compared to patients with intermediate cytogenetics (37% vs 79%). Median remission duration and overall survival were 3 and 9 months, respectively and not different between ID and SD patients. Although the treatment-related toxicity is high, a high CR rate can be obtained in these poor-risk AML patients with the use of intensive chemotherapy in combination with G-CSF, although the role of the latter is still to be proven. Results remain especially poor in patients with unfavorable cytogenetics. New approaches are needed to maintain remission in these high-risk AML patients.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jan
|
| pubmed:issn |
0887-6924
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
11
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
16-21
|
| pubmed:dateRevised |
2007-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:9001413-Adult,
pubmed-meshheading:9001413-Aged,
pubmed-meshheading:9001413-Anemia, Refractory, with Excess of Blasts,
pubmed-meshheading:9001413-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:9001413-Bone Marrow Examination,
pubmed-meshheading:9001413-Bone Marrow Transplantation,
pubmed-meshheading:9001413-Combined Modality Therapy,
pubmed-meshheading:9001413-Cytarabine,
pubmed-meshheading:9001413-Feasibility Studies,
pubmed-meshheading:9001413-Female,
pubmed-meshheading:9001413-Follow-Up Studies,
pubmed-meshheading:9001413-Granulocyte Colony-Stimulating Factor,
pubmed-meshheading:9001413-Humans,
pubmed-meshheading:9001413-Idarubicin,
pubmed-meshheading:9001413-Leukemia, Myeloid, Acute,
pubmed-meshheading:9001413-Male,
pubmed-meshheading:9001413-Middle Aged,
pubmed-meshheading:9001413-Neoplasms, Second Primary,
pubmed-meshheading:9001413-Prospective Studies,
pubmed-meshheading:9001413-Remission Induction
|
| pubmed:year |
1997
|
| pubmed:articleTitle |
Intensive chemotherapy with idarubicin, cytosine arabinoside, and granulocyte colony-stimulating factor (G-CSF) in patients with secondary and therapy-related acute myelogenous leukemia. Club de Réflexion en Hématologie.
|
| pubmed:affiliation |
Department of Hematology, Hôpital Beaujon, Clichy, France.
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Multicenter Study,
Clinical Trial, Phase II
|